

AMENDMENTS TO THE CLAIMS

Claims 1-7 (canceled).

Claim 8 (previously presented) A method of inhibiting cell-cell interaction, comprising:

contacting the cells with an antibody directed against a peptide consisting of SEQ ID No. 41 or consisting of SEQ ID No. 2 that is derived from a cell surface vascular endothelial growth factor and type I collagen inducible protein (VCIP) consisting of SEQ ID No. 13, wherein said contact with the antibody blocks binding of $\alpha v\beta 3$ and/or $\alpha 5\beta 1$ integrins to the cell surface vascular endothelial growth factor and type I collagen inducible protein (VCIP), thereby inhibiting the cell-cell interaction.

Claim 9 (original) The method of claim 8, wherein said cell-cell interaction is mediated by integrin ligand.

Claims 10-13 (canceled)

Claim 14 (previously presented) The method of claim 8, wherein said cell-cell interaction contributes to inflammation or angiogenesis.

Claim 15 (currently amended) A method of treating inhibiting tumor growth, inflammation and/or angiogenesis in a patient with a pathological condition caused by integrin-mediated cell-cell interaction, comprising:

administering to said patient an antibody directed against a peptide consisting of SEQ ID No. 41 or consisting of SEQ ID No. 2 that is derived from a cell surface vascular endothelial growth factor and type I collagen inducible protein (VCIP) consisting of SEQ ID No. 13, wherein said antibody blocks binding of $\alpha v \beta 3$ and/or $\alpha 5 \beta 1$ integrins to the cell surface vascular endothelial growth factor and type I collagen inducible protein, thereby treating inhibiting tumor growth, inflammation and/or angiogenesis in the patient with the pathological condition caused by the integrin-mediated cell-cell interaction.

Claims 16-31 (canceled)

Claim 32 (previously presented) A method of inhibiting angiogenesis and the formation of capillaries in a patient in need of such a treatment, comprising:

administering to said patient a pharmacologically effective amount of an antibody directed against a peptide consisting of SEQ ID No. 41 or consisting of SEQ ID No. 2 that is derived from vascular endothelial growth factor and type I collagen inducible protein (VCIP) consisting of SEQ ID No. 13, wherein said antibody inhibits $\alpha v \beta 3$ and/or $\alpha 5 \beta 1$ integrin-mediated cell-cell

interaction, thereby inhibiting angiogenesis and the formation of capillaries in the patient in need of such a treatment .

Claims 33-41 (canceled).